FDG PET/CT评估的完全代谢缓解:FOLFOXIRI-贝伐珠单抗一线治疗BRAFV600E突变转移性结直肠癌
本文报道一例60岁女性BRAFV600E突变转移性结直肠癌患者,接受FOLFOXIRI-贝伐珠单抗一线治疗后,FDG PET/CT评估为完全代谢缓解并维持13个月;作者指出此前文献仅报道过1例经FDG PET/CT评估达完全缓解的BRAF突变mCRC,且采用FOLFIRI-西妥昔单抗双药方案,并认为FDG PET/CT正成为mCRC靶向药物疗效评估的有用手段。
要点
- FOLFOXIRI联合贝伐珠单抗方案被列为BRAF突变mCRC一线治疗。
- 该例60岁女性经FDG PET/CT评估为完全代谢缓解,维持13个月。
- 作者认为FDG PET/CT正成为mCRC靶向治疗疗效评估的有用手段。
核心结论
- 作者报道一例BRAFV600E突变转移性结直肠癌患者经FOLFOXIRI-贝伐珠单抗一线治疗后,FDG PET/CT评估为完全代谢缓解并维持13个月。
研究设计与样本
- 本文为病例报告,报道1例60岁女性BRAFV600E突变转移性结直肠癌患者。
主要发现
- 该60岁女性患者接受FOLFOXIRI-贝伐珠单抗一线治疗,FDG PET/CT评估为完全代谢缓解,维持13个月。
- 作者指出此前文献仅报道过1例经FDG PET/CT评估达完全缓解的BRAF突变mCRC,该例接受FOLFIRI-西妥昔单抗双药方案治疗。
关键数值与推荐
- FOLFOXIRI联合贝伐珠单抗方案被列为BRAF突变转移性结直肠癌一线治疗。
- 临床试验中该方案的疗效证据仅基于CT评估的部分形态学缓解。
临床怎么用
- 作者认为FDG PET/CT正成为mCRC靶向药物疗效评估的有用手段。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Triplet chemotherapy (FOLFOXIRI) + bevacizumab regimen is indicated as first-line treatment of BRAF-mutated metastatic colorectal cancer (mCRC). Nevertheless, its proven therapeutic efficacy in clinical trials was solely based on partial morphologic responses assessed by CT. To date, only 1 case of complete response assessed by FDG PET/CT was reported in literature in BRAF-mutated mCRC, but treated with doublet chemotherapy (FOLFIRI) + cetuximab regimen. We report a complete metabolic response assessed by FDG PET/CT, maintained over time (13 months) in a 60-year-old woman with BRAF-mutated mCRC treated by FOLFOXIRI-bevacizumab. This also confirms that FDG PET/CT is emerging as a useful approach for therapeutic assessment of targeted drugs in mCRC.
引用
- Amrane K, le Pennec R, Schick U, et al. Complete Metabolic Response Assessed by FDG PET/CT to FOLFOXIRI-Bevacizumab in First-Line Treatment of BRAFV600E Mutated Metastatic Colorectal Cancer. Clin Nucl Med. 2020. PMID: 32657876. doi:10.1097/RLU.0000000000003190
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。